132 related articles for article (PubMed ID: 32511702)
1. Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
Mat Salleh NH; Rahman MFA; Samsusah S; De Silva JR; Ng DC; Ghozali AH; Tan JH; Lai MY; Amir A; Liew JWK; Lau YL
Trans R Soc Trop Med Hyg; 2020 Sep; 114(9):700-703. PubMed ID: 32511702
[TBL] [Abstract][Full Text] [Related]
2. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
[TBL] [Abstract][Full Text] [Related]
3. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
4. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
[TBL] [Abstract][Full Text] [Related]
5. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
[No Abstract] [Full Text] [Related]
6. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
[TBL] [Abstract][Full Text] [Related]
8. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
9. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS
Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
[No Abstract] [Full Text] [Related]
11. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
[TBL] [Abstract][Full Text] [Related]
12. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
Commons RJ; Rajasekhar M; Edler P; Abreha T; Awab GR; Baird JK; Barber BE; Chu CS; Cui L; Daher A; Gonzalez-Ceron L; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Lidia K; Llanos-Cuentas A; Longley RJ; Pereira DB; Pasaribu AP; Pukrittayakamee S; Rijal KR; Sutanto I; Taylor WRJ; Thanh PV; Thriemer K; Vieira JLF; Watson JA; Zuluaga-Idarraga LM; White NJ; Guerin PJ; Simpson JA; Price RN;
Lancet Infect Dis; 2024 Feb; 24(2):172-183. PubMed ID: 37748496
[TBL] [Abstract][Full Text] [Related]
13. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.
Mwaiswelo RO; Ngasala B; Msolo D; Kweka E; Mmbando BP; Mårtensson A
Malar J; 2022 Mar; 21(1):84. PubMed ID: 35279143
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis.
Park YA; Park KH; Yoon HY; Yee J; Gwak HS
Travel Med Infect Dis; 2022; 48():102333. PubMed ID: 35452835
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
Hwang J; Alemayehu BH; Reithinger R; Tekleyohannes SG; Takele Teshi ; Birhanu SG; Demeke L; Hoos D; Melaku Z; Kassa M; Jima D; Malone JL; Nettey H; Green M; Poe A; Akinyi S; Udhayakumar V; Kachur SP; Filler S
PLoS One; 2013; 8(5):e63433. PubMed ID: 23717423
[TBL] [Abstract][Full Text] [Related]
16. Delayed gametocyte clearance in
Salazar YEAR; Louzada J; Puça MCSdB; Guimarães LFF; Vieira JLF; Siqueira AMd; Gil JP; Brito CFAd; Sousa TNd
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0120423. PubMed ID: 38411047
[TBL] [Abstract][Full Text] [Related]
17. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Bennett JW; Pybus BS; Yadava A; Tosh D; Sousa JC; McCarthy WF; Deye G; Melendez V; Ockenhouse CF
N Engl J Med; 2013 Oct; 369(14):1381-2. PubMed ID: 24088113
[No Abstract] [Full Text] [Related]
18. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.
Bassat Q
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1325. PubMed ID: 22216359
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
